Updated on 4 June 2013
Sino Biopharmaceutical's major product, Kaishi injections, which is produced by Beijing Tide works, is the first micro-sphere target sustained release medicine in China to improve cardio-cerebral microcirculation blockage.
Sino Biopharmaceutical's Tianqingning injections, a plasma-volume expander for patients with blood volume deficiencies, have shown strong performance in the market and its medicine for hepatitis B, Runzhong (Entecavir) dispersible tablet, has obtained a product approval certificate and production approval.
Runzhong dispersible tablet is the latest generation of guanine nucleoside analogue oral medicine used mainly for the treatment of hepatitis B. It inhibits viral replication and has lower risk of triggering the emergence of